HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204. Ladenburg Thalmann & Co. Inc. acted as ex ...

Core Insights - STRATA Skin Sciences, Inc. has reported growth in partner clinics utilizing its Elevate 360 consulting services platform, which aims to optimize revenue through best practices in marketing, reimbursement, and patient retention [1][2][4] Group 1: E360 Program Impact - The E360 program has been adopted by 99 out of approximately 844 clinics under STRATA's XTRAC usage agreement, leading to an average growth of 7% year over year for participating clinics [4] - A partner clinic that adopted the E360 program expanded from two to nine clinics, resulting in revenue of $61,800 for STRATA in the first half of 2025, indicating significant growth potential [6] Group 2: Business Optimization - The E360 program assists clinics in managing the entire treatment process, from patient referrals to securing insurance reimbursements and scheduling follow-up visits, thereby enhancing patient retention [3][5] - STRATA's initiatives under the E360 program include turn-key marketing solutions and optimization of business systems, which have shown quick improvements in partner clinic financial performance [2][7] Group 3: Market Potential - The company anticipates continued growth opportunities from recent improvements in reimbursement policies that expand treatment indications for XTRAC lasers, including conditions like vitiligo and autoimmune skin disorders [7] - The E360 program is positioned to help clinics meet patient demand and realize market potential, suggesting a strategic focus on enhancing clinic operations and patient care [7]

HORSHAM, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204, in a ...

HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and CEO of Strata Skin Sciences will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lott ...

Strata continues to work closely with CMS to ensure a rapid implementation of the extended codesHORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today affirms its patent portfolio provides intellectual property (IP) and market exclusivity for combination therapies of its XTRAC excimer lase ...

Core Insights - STRATA Skin Sciences, Inc. reported its financial results for the second quarter of 2025, highlighting a strategic focus on expanding its patient population through newly approved reimbursement codes for its XTRAC Excimer laser treatment [1][3]. Financial Performance - Revenue for Q2 2025 was $7.7 million, a decrease of 9% compared to Q2 2024 [4]. - Global recurring revenue was $5.1 million, down 4% year-over-year, while equipment revenue decreased by 18% to $2.5 million [4]. - Gross profit for the quarter was $4.3 million, representing 56% of revenue, down from $5.0 million in the same quarter of the previous year [4]. - Total operating expenses increased to $6.5 million from $5.5 million in the prior-year period [5]. - The net loss for Q2 2025 was $2.5 million, or a loss per share of $0.60, compared to a net loss of $0.1 million, or a loss per share of $0.03, in Q2 2024 [5][24]. Operational Highlights - The company is managing costs while expanding its patient pool through direct-to-consumer (DTC) efforts and strengthening partnerships with practice partners [3]. - STRATA has seen a historic expansion of CPT codes for reimbursement, effectively tripling the covered patient population in the U.S. [8]. - The average gross billings per device increased by 2.7% to $5,512 compared to the prior-year period [8]. - The company removed 21 underperforming XTRAC devices and placed 19, marking the highest number of placements in six quarters [8]. Cash Position - As of June 30, 2025, cash and cash equivalents were $6.0 million, despite a payment of $1.3 million in restricted cash related to sales tax accruals [6][8].

Core Insights - STRATA Skin Sciences is working with CMS to obtain temporary codes for expanded reimbursement of its XTRAC excimer laser treatment, aiming for implementation as early as the 2026 rule cycle [2][3] - The American Medical Association has approved updates to CPT codes, expanding reimbursement eligibility for XTRAC treatments to include various inflammatory and autoimmune skin conditions effective January 1, 2027 [2] - STRATA's efforts could potentially triple the addressable patient population, benefiting over 30 million individuals with chronic skin conditions [3] Company Developments - STRATA has received significant support from legislators, patient advocacy groups, and academic leaders, reinforcing confidence in the efficacy of Excimer Laser therapy [4] - Recent peer-reviewed studies have confirmed the safety and effectiveness of combining 308-nm excimer laser therapy with JAK inhibitors for treating vitiligo, with one study showing a 100% overall response rate [5][6] - The company is involved in ongoing litigation against LaserOptek America, with the Federal District Court agreeing to add LaserOptek Korea as a defendant, indicating potential for significant damages [7][8] Product and Market Strategy - STRATA's XTRAC excimer laser is positioned as a leading drug-free option for treating skin conditions, with a focus on enhancing patient outcomes [4][9] - The company offers a unique Partnership Program that includes a fee per treatment cost structure, on-site training, and marketing support to promote its technologies [11] - STRATA's intellectual property portfolio includes patents for localized treatment methods, positioning the company for future growth in the dermatology market [9]

Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing innovative products for dermatologic conditions such as psoriasis, vitiligo, and acne [5] - The company's product offerings include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System [5] Upcoming Financial Results - STRATA will report its second quarter 2025 financial results on August 13, 2025, after the market closes [1] - A conference call will be held on the same day at 4:30 p.m. ET to review the financial results and provide updates on corporate developments [2] Conference Call Details - Interested parties can listen to the conference call by dialing 1-866-524-3160 for domestic calls or 1-412-317-6760 for international calls, with a recommendation to join approximately 10 minutes prior to the start time [3] - A telephonic replay of the call will be available until August 20, 2025, and a webcast replay will be accessible approximately one hour after the live call until February 13, 2026 [4] Partnership Program - STRATA offers a unique Partnership Program that includes a fee per treatment cost structure instead of requiring equipment purchase, installation, and use [6] - The program provides on-site training for practice personnel, service and maintenance of equipment, dedicated account and customer service associates, and co-op advertising support [6]

Core Viewpoint - STRATA Skin Sciences, Inc. has announced that the American Medical Association has accepted revisions to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and autoimmune skin conditions beyond psoriasis, reflecting over 20 years of clinical evidence and real-world use of STRATA's XTRAC Excimer Lasers [1][2][3] Reimbursement Expansion - The updated CPT codes align with current FDA clearances and commercial payer coverage guidelines, expected to reduce systemic denials and the need for prior authorizations [2] - The revised codes explicitly include treatment for conditions such as vitiligo, atopic dermatitis, mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-cell lymphoma, potentially increasing the patient base from 10 million psoriasis patients to over 30 million [2][3] Clinical Significance - STRATA's CEO emphasized that this milestone reflects the broader clinical utility of the XTRAC excimer laser, supporting the mission to expand access to non-drug dermatologic solutions [3][5] - Experts in dermatology highlighted the importance of excimer lasers in transforming treatment for conditions like vitiligo and atopic dermatitis, validating the broader clinical value of the technology [3][4] Market Impact - The expanded CPT code coverage is expected to generate significant commercial growth, with non-psoriasis indications already accounting for approximately 30% of excimer laser treatment volume [3][6] - STRATA anticipates broader adoption of the XTRAC platform beyond the existing 1,400 clinics and 4,000 medical providers, supporting accelerated revenue growth under its recurring-use business model [3][6] Collaboration and Advocacy - STRATA has collaborated with leading clinical Key Opinion Leaders, patient advocacy groups, and the American Academy of Dermatology to advocate for the expanded indications of the XTRAC excimer laser [7]

Core Insights - STRATA Skin Sciences, Inc. reported a modest revenue increase of 1% year-over-year for Q1 2025, totaling $6.8 million, with gross margins improving significantly by nearly 800 basis points to 53.5% [6][10][24] - The company has successfully executed its direct-to-consumer strategy, resulting in a 32% increase in unique psoriasis patients and a 128% increase in unique acne patients compared to the prior year [4] - International revenue grew by 8% in Q1 2025, contributing to 36% of total revenue, and is expected to continue growing as global tariff uncertainties resolve [5] Financial Performance - Revenue for Q1 2025 was $6.8 million, a 1% increase from Q1 2024, with global recurring revenue at $4.7 million and equipment revenue at $2.1 million, both up approximately 1% [6][10] - Gross profit for Q1 2025 was $3.6 million, representing 53.5% of revenue, compared to $3.1 million or 45.6% of revenue in Q1 2024 [6][24] - Total operating expenses decreased by 5% to $5.7 million, with significant reductions in engineering and product development expenses by 60% [7][24] Loss and Cash Position - The net loss for Q1 2025 was $2.4 million, or a loss per share of $0.58, an improvement from a net loss of $3.4 million or $0.96 per share in Q1 2024 [7][24] - Cash, cash equivalents, and restricted cash at the end of Q1 2025 were $7.8 million, down from $8.6 million at the beginning of the period [8][26] Strategic Developments - The company is focused on enhancing its direct-to-consumer marketing efforts and building a strong franchise in dermatology and aesthetics [20] - STRATA's partnership program offers innovative treatment technologies with a fee-per-treatment cost structure, which is expected to drive further growth [19][18]